non-small cell lung cancer

Research Reports

The Impact of Decreasing Variability in Surgical Care Through a Structured Multi-Disciplinary Thoracic Oncology Program

09/19/2017

Clinton D Protack, MD, PhD

Justin D Blasberg, MD

Jia Liu, MD

Shamini Parameswaran, MD

Daniel J Boffa, MD

Lynn T Tanoue, MD

Frank C Detterbeck, MD

Anthony W Kim, MD, MS, FACS, FCCP

Abstract: In order to identify the impact of decreasing variability in surgical care through a structured multidisciplinary thoracic oncology program (TOP), the researchers observed changes following the...

...

09/19/2017

Journal of Clinical Pathways

Research in Review

Resistance Mutations Predict Metastatic Patterns in NSCLC

08/17/2017

JCP Editors

Specific gene rearrangements associated with increased resistance to standard therapy may predict different metastasis distributions in patients with non-small cell lung cancer (NSCLC), according to research...

...

08/17/2017

Journal of Clinical Pathways

Research in Review

Double Dosage of ALK Inhibitor Improves Outcomes in NSCLC

08/09/2017

JCP Editors

Increasing the standard dose of an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of non-small cell lung cancer (NSCLC) improves objective response rates (ORR) by 9% with limited additional toxicity,...

...

08/09/2017

Journal of Clinical Pathways

Research in Review

NSCLC Prognostic Index Considers Personal Characteristics to Better Predict Outcomes

07/26/2017

JCP Editors

The Lung Cancer Prognostic Index provides personalized and disease-specific prognostic information for patients with non-small cell lung cancer (NSCLC) and may result in better survival outcomes, according to a...

The...

07/26/2017

Journal of Clinical Pathways

Research in Review

NSCLC Treatment Patterns, OS Data Aids Clinical Practice Benchmark Initiatives

06/26/2017

JCP Editors

Results of a recent study offer insight into the effects of shifting treatment patterns of non-small cell lung cancer (NSCLC) treatment on patient outcomes, and for furthering community oncology benchmark...

...

06/26/2017

Journal of Clinical Pathways

Research in Review

PD-1 Inhibitor Improves Response Rates, Survival Times in Certain Patients With NSCLC

06/23/2017

JCP Editors

A programmed death 1 (PD-1) inhibitor is associated with similar efficacy to chemotherapy in patients with non-small cell lung cancer (NSCLC), but improves response rates and survival times in subgroups of patients,...

A...

06/23/2017

Journal of Clinical Pathways

Research in Review

Earlier Endpoint May Be Predictive of Lung Cancer Therapy Outcomes

06/16/2017

JCP Editors

A novel intermediate endpoint could be a useful measure in clinical trials for metastatic non-small cell lung cancer (mNSCLC), according to a recent study published in JAMA (published online June 15, 2017;...

A...

06/16/2017

Journal of Clinical Pathways

Research in Review

Personalized Dosing More Cost-Effective for NSCLC Treatment

06/15/2017

JCP Editors

A recent budget analysis evaluated the costs, safety, and efficacy of personalized dosing compared with fixed dosing of standard-of-care treatment for non-small cell lung cancer, presented at the 2017 ASCO Annual...

A...

06/15/2017

Journal of Clinical Pathways

Research in Review

Standard of Care Shift in ALK-Positive Lung Cancer

06/12/2017

JCP Editors

A second-generation inhibitor delays anaplastic lymphoma kinase (ALK)-positive lung cancer growth for a median of 15 months longer and causes fewer adverse events than the current standard of care, according to a new...

A...

06/12/2017

Journal of Clinical Pathways

Research in Review

PD-L1 Testing Uncommon Among NSCLC Patients on Immunotherapy

06/03/2017

JCP Editors

Few patients treated with immunotherapy for metastatic non–small cell lung cancer (NSCLC) at United States community practices receive appropriate programmed death-ligand 1 (PD-L1) expression testing, according to...

Few...

06/03/2017

Journal of Clinical Pathways